Findings

What do systematic reviews say?

6 questions · 6 findings · 2 reviews · Gut

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 16.7%Moderate 5 · 83.3%High 0 · 0%

Certolizumab pegol vs placebo

Failure to maintain clinical remission at end of study · people with Crohn's disease who responded to CZP remission‐induction treatment

Certolizumab pegol probably leads to lower failure to maintain clinical remission at week 26(1 RCT, 428… compared with placebo (moderate certainty).

1 finding from 1 review

Certolizumab pegol for maintenance of medically induced remission in Crohn’s disease 2022 · Cochrane Headline outcomes only
RR 0.73 [0.63, 0.85]
Studies not reported
Moderate

Certolizumab pegol vs placebo

Failure to maintain clinical response · people with Crohn's disease who responded to CZP remission‐induction treatment

Certolizumab pegol probably leads to lower failure to maintain clinical response at week 26(1 RCT, 428… compared with placebo (moderate certainty).

1 finding from 1 review

Certolizumab pegol for maintenance of medically induced remission in Crohn’s disease 2022 · Cochrane Headline outcomes only
RR 0.58 [0.48, 0.71]
Studies not reported
Moderate

Certolizumab pegol vs placebo

Any severe adverse event during maintenance treatment · people with Crohn's disease who responded to CZP remission‐induction treatment

Certolizumab pegol showed no clear difference in serious adverse events during remission maintenance treatment(1 RCT,… compared with placebo (low certainty).

1 finding from 1 review

Certolizumab pegol for maintenance of medically induced remission in Crohn’s disease 2022 · Cochrane Headline outcomes only
RR 0.84 [0.4, 1.78]
Studies not reported
Low

Certolizumab pegol vs placebo

Clinical remission · Patients with active Crohn's disease

Certolizumab pegol probably leads to higher clinical remission compared with placebo (moderate certainty).

1 finding from 1 review

Certolizumab pegol for induction of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 1.36 [1.11, 1.66]
4 studies · 1485 participants
Moderate

Certolizumab pegol vs placebo

Clinical response · Patients with active Crohn's disease

Certolizumab pegol probably leads to higher clinical response compared with placebo (moderate certainty).

1 finding from 1 review

Certolizumab pegol for induction of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 1.29 [1.09, 1.53]
4 studies · 1485 participants
Moderate

Certolizumab pegol vs placebo

Serious adverse events · Patients with active Crohn's disease

Certolizumab pegol showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Certolizumab pegol for induction of remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 1.35 [0.93, 1.97]
4 studies · 1485 participants
Moderate